Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse ...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
10 Dec 2019
Identifying prognostic constellations of driver mutations in acute myeloid leuka...
Dr Charles Mullighan - St. Jude Children's Research Hospital, Memphis, USA
Identifying prognostic constellations of driver mutations in acute myeloid leukaemia and myelodysplastic syndromes ( Dr Charles Mullighan -  St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2019
CANDOR: Triple drug combo delays disease progression in stubborn multiple myelom...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
CANDOR: Triple drug combo delays disease progression in stubborn multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
Maintenance therapy with CC-486 for acute myeloid leukaemia
Prof Andrew Wei - Monash University, Melbourne, Australia
Maintenance therapy with CC-486 for acute myeloid leukaemia ( Prof Andrew Wei - Monash University, Melbourne, Australia )
10 Dec 2019
Daratumuab, carfilzomib and dexamethasone increases survival in patients with re...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
Daratumuab, carfilzomib and dexamethasone increases survival in patients with relapsed/refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )
10 Dec 2019
Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and...
Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA
Exploring the pathogenesis of AML and myelodysplastic syndromes using genome and transcriptome sequencing ( Dr Ilaria Iacobucci - St. Jude Children's Research Hospital, Memphis, USA )
10 Dec 2019
QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients wi...
Prof Andrew Wei - Monash University, Melbourne, Australia
QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission ( Prof Andrew Wei - Monash University, Melbourne, Australia )
10 Dec 2019
Blinatumomab demonstrates superior efficacy compared to chemotherapy in children...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
Blinatumomab demonstrates superior efficacy compared to chemotherapy in children and young adults with relapsed B-ALL ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )
10 Dec 2019
Multiple myeloma highlights from ASH 2019
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
Multiple myeloma highlights from ASH 2019 ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
10 Dec 2019
MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractor...
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lymphocytic leukaemia ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
9 Dec 2019
Glasdegib in combination with azacitidine in patients with untreated higher-risk...
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Glasdegib in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes and AML ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
9 Dec 2019
Addressing the treatment gap for patients with relapsed/refractory primary syste...
Prof Evangelos Terpos and Prof Efstathios Kastritis
Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results ( Prof Evangelos Terpos and Prof Efstathios Kastritis )
9 Dec 2019